2025 Q4 -tulosraportti
Vain PDF
24 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 210 | - | - | ||
| 608 | - | - | ||
| 1 000 | - | - | ||
| 2 100 | - | - | ||
| 31 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·4 t sittenIT'S SATURDAY. THE STOCK MARKET IS CLOSED. BUT THE GAME IS ON. ♟️ While most people spend the weekend stressing over red figures or checking if their index fund moved 0.1 % on Friday… Right now, the Circio-team is getting ready for Boston. Destination: ASGCT. 🇺🇸🧬 They are not traveling there to mingle and drink coffee. They are traveling there with data. In vivo-data. AAV-data. Eye. Heart. CNS. 60x expression. 22x higher output at 10x lower dose. A message that the gene therapy community actually understands: More effect per biological input. Lower dose. Better safety-margin. Potential solution to one of the biggest bottlenecks in gene therapy. And in the background lies the rest of the stack: Acuitas. LNP. In vivo CAR-T. TraffikGene. Non-viral delivery. Partner-funded in vivo-testing. This is not a regular conference. This is the place where technology meets the field. Where people who actually understand AAV, dose, delivery, expression and safety can see what circVec is trying to solve. Our job is simple now. We have read the data. We have understood the asymmetry. We have taken the risk before everything is fully proven. Now it's the company's turn to take the stage. Boston awaits. The market is closed. But the game is on. Log off. Enjoy Saturday. Next week the show starts. We know what we own. ♟️🧱🍷
10 t sitten10 t sitten
·15 t sittenVwap for the 1st day of the valuation period up to and including May 22nd was kr 9.3. TR is priced as if the share is to have a vwap from May 8-22 below 4 kroner.
·3 t sittenIt was written above VWAP day 1 is 9.3. I got: Day 1 VWAP ≈ 76.4m / 8.27m ≈ 9.24 This period will be interesting to follow: spikes up and down fake moves retail-driven volatility potential shorts shorts covering Intraday volatility Messy price development: small investors, trading-flow, short-term speculation So away with all the noise - optimal development for warrants: Early: The price should be weak/flat so that VWAP is kept low and provides a low entry price (K). Middle: The price should stabilize to lock in a low and predictable VWAP level. Late: The price should start to rise to build momentum without lifting VWAP too much. After 10 vwap: The price should continue up so that the gap between low K and high market price maximizes profit.
·1 t sittenWrong, the turnover Day 1 was not 76.4m but 77.0 and VWAP 9.31 Nordnet is showing errors (again)
·15 t sittenMany thanks to everyone who replied to the post about B:T measurement; ( should have replied in the thread; but late, tired, narrow vision; even with reading glasses, I found the dialogy on iPhone ) 😴 I suspected I must have misunderstood; good to get it confirmed. Good friend with Chat GPT but have been busy with other questions there lately. Have been in Circio a little tidl..solsolgte and put everything into Blue Nord. Back in Friday. Am an optimist by nature; but also a bit ambivalent and impulsive - so greatly appreciate relatively objective viewpoints. A really good weekend to most here ☀️😎☀️- ·16 t sittenRegarding the abstracts for ASGCT, you will find Circio on page 921-922·5 t sittenAlfur, that was not the point of the post either. Some wondered what happened to it and some misinformation in recent days. People can read the abstract themselves,, plain and simple. Next deadline is May 10. Normally to release newer data the day before or the same day. In 2025 Circio came with new data the same day. What they cannot do, is to change the abstract
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
24 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenIT'S SATURDAY. THE STOCK MARKET IS CLOSED. BUT THE GAME IS ON. ♟️ While most people spend the weekend stressing over red figures or checking if their index fund moved 0.1 % on Friday… Right now, the Circio-team is getting ready for Boston. Destination: ASGCT. 🇺🇸🧬 They are not traveling there to mingle and drink coffee. They are traveling there with data. In vivo-data. AAV-data. Eye. Heart. CNS. 60x expression. 22x higher output at 10x lower dose. A message that the gene therapy community actually understands: More effect per biological input. Lower dose. Better safety-margin. Potential solution to one of the biggest bottlenecks in gene therapy. And in the background lies the rest of the stack: Acuitas. LNP. In vivo CAR-T. TraffikGene. Non-viral delivery. Partner-funded in vivo-testing. This is not a regular conference. This is the place where technology meets the field. Where people who actually understand AAV, dose, delivery, expression and safety can see what circVec is trying to solve. Our job is simple now. We have read the data. We have understood the asymmetry. We have taken the risk before everything is fully proven. Now it's the company's turn to take the stage. Boston awaits. The market is closed. But the game is on. Log off. Enjoy Saturday. Next week the show starts. We know what we own. ♟️🧱🍷
- 10 t sitten10 t sitten
- ·15 t sittenVwap for the 1st day of the valuation period up to and including May 22nd was kr 9.3. TR is priced as if the share is to have a vwap from May 8-22 below 4 kroner.·3 t sittenIt was written above VWAP day 1 is 9.3. I got: Day 1 VWAP ≈ 76.4m / 8.27m ≈ 9.24 This period will be interesting to follow: spikes up and down fake moves retail-driven volatility potential shorts shorts covering Intraday volatility Messy price development: small investors, trading-flow, short-term speculation So away with all the noise - optimal development for warrants: Early: The price should be weak/flat so that VWAP is kept low and provides a low entry price (K). Middle: The price should stabilize to lock in a low and predictable VWAP level. Late: The price should start to rise to build momentum without lifting VWAP too much. After 10 vwap: The price should continue up so that the gap between low K and high market price maximizes profit.·1 t sittenWrong, the turnover Day 1 was not 76.4m but 77.0 and VWAP 9.31 Nordnet is showing errors (again)
- ·15 t sittenMany thanks to everyone who replied to the post about B:T measurement; ( should have replied in the thread; but late, tired, narrow vision; even with reading glasses, I found the dialogy on iPhone ) 😴 I suspected I must have misunderstood; good to get it confirmed. Good friend with Chat GPT but have been busy with other questions there lately. Have been in Circio a little tidl..solsolgte and put everything into Blue Nord. Back in Friday. Am an optimist by nature; but also a bit ambivalent and impulsive - so greatly appreciate relatively objective viewpoints. A really good weekend to most here ☀️😎☀️
- ·16 t sittenRegarding the abstracts for ASGCT, you will find Circio on page 921-922·5 t sittenAlfur, that was not the point of the post either. Some wondered what happened to it and some misinformation in recent days. People can read the abstract themselves,, plain and simple. Next deadline is May 10. Normally to release newer data the day before or the same day. In 2025 Circio came with new data the same day. What they cannot do, is to change the abstract
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 210 | - | - | ||
| 608 | - | - | ||
| 1 000 | - | - | ||
| 2 100 | - | - | ||
| 31 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
24 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenIT'S SATURDAY. THE STOCK MARKET IS CLOSED. BUT THE GAME IS ON. ♟️ While most people spend the weekend stressing over red figures or checking if their index fund moved 0.1 % on Friday… Right now, the Circio-team is getting ready for Boston. Destination: ASGCT. 🇺🇸🧬 They are not traveling there to mingle and drink coffee. They are traveling there with data. In vivo-data. AAV-data. Eye. Heart. CNS. 60x expression. 22x higher output at 10x lower dose. A message that the gene therapy community actually understands: More effect per biological input. Lower dose. Better safety-margin. Potential solution to one of the biggest bottlenecks in gene therapy. And in the background lies the rest of the stack: Acuitas. LNP. In vivo CAR-T. TraffikGene. Non-viral delivery. Partner-funded in vivo-testing. This is not a regular conference. This is the place where technology meets the field. Where people who actually understand AAV, dose, delivery, expression and safety can see what circVec is trying to solve. Our job is simple now. We have read the data. We have understood the asymmetry. We have taken the risk before everything is fully proven. Now it's the company's turn to take the stage. Boston awaits. The market is closed. But the game is on. Log off. Enjoy Saturday. Next week the show starts. We know what we own. ♟️🧱🍷
- 10 t sitten10 t sitten
- ·15 t sittenVwap for the 1st day of the valuation period up to and including May 22nd was kr 9.3. TR is priced as if the share is to have a vwap from May 8-22 below 4 kroner.·3 t sittenIt was written above VWAP day 1 is 9.3. I got: Day 1 VWAP ≈ 76.4m / 8.27m ≈ 9.24 This period will be interesting to follow: spikes up and down fake moves retail-driven volatility potential shorts shorts covering Intraday volatility Messy price development: small investors, trading-flow, short-term speculation So away with all the noise - optimal development for warrants: Early: The price should be weak/flat so that VWAP is kept low and provides a low entry price (K). Middle: The price should stabilize to lock in a low and predictable VWAP level. Late: The price should start to rise to build momentum without lifting VWAP too much. After 10 vwap: The price should continue up so that the gap between low K and high market price maximizes profit.·1 t sittenWrong, the turnover Day 1 was not 76.4m but 77.0 and VWAP 9.31 Nordnet is showing errors (again)
- ·15 t sittenMany thanks to everyone who replied to the post about B:T measurement; ( should have replied in the thread; but late, tired, narrow vision; even with reading glasses, I found the dialogy on iPhone ) 😴 I suspected I must have misunderstood; good to get it confirmed. Good friend with Chat GPT but have been busy with other questions there lately. Have been in Circio a little tidl..solsolgte and put everything into Blue Nord. Back in Friday. Am an optimist by nature; but also a bit ambivalent and impulsive - so greatly appreciate relatively objective viewpoints. A really good weekend to most here ☀️😎☀️
- ·16 t sittenRegarding the abstracts for ASGCT, you will find Circio on page 921-922·5 t sittenAlfur, that was not the point of the post either. Some wondered what happened to it and some misinformation in recent days. People can read the abstract themselves,, plain and simple. Next deadline is May 10. Normally to release newer data the day before or the same day. In 2025 Circio came with new data the same day. What they cannot do, is to change the abstract
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 210 | - | - | ||
| 608 | - | - | ||
| 1 000 | - | - | ||
| 2 100 | - | - | ||
| 31 | - | - |
Välittäjätilasto
Dataa ei löytynyt